Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer This retrospective study included PWH treated with anti–PD-1- or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback